Phase II trial of gefitinib in recurrent glioblastoma.
暂无分享,去创建一个
Allan H Friedman | R. McLendon | A. Friedman | D. Bigner | J. Dancey | H. Friedman | D. Reardon | J. Rich | J. Sampson | J. Vredenburgh | Roger E McLendon | Darell D Bigner | Jeremy N Rich | David A Reardon | J. Herndon | J. Quinn | James J Vredenburgh | James E Herndon | Jennifer A Quinn | Henry S Friedman | John H Sampson | Janet E Dancey | S. Tourt-Uhlig | C. Wikstrand | Timothy T Stenzel | T. Stenzel | Jeannette M Dowell | Terry Peery | Kara L Penne | Carol J Wikstrand | Lauren B Van Duyn | James C Kao | B K Ahmed Rasheed | Sandra E Tourt-Uhlig | K. Penne | J. Dowell | B. Ahmed Rasheed | T. Peery
[1] P. Humphrey,et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. , 1988, Cancer research.
[2] Hermona Soreq,et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.
[3] W. Curran,et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.
[4] W. Cavenee,et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[5] D. Bigner,et al. Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin Gliomas, neuroblastomas, and melanomas , 1982, Journal of Neuroimmunology.
[6] G Milano,et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’) , 2002, British Journal of Cancer.
[7] M. Kris,et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] N. Morita,et al. Function of aberrant EGFR in malignant gliomas , 2006, Brain Tumor Pathology.
[9] E. Vokes,et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Humphrey,et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. , 1990, Cancer research.
[11] B. de Camargo,et al. A simple cost-effective lactate dehydrogenase level measurement can stratify patients with Ewing's tumor into low and high risk. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] C. James,et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[13] J. Baselga,et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. von Deimling,et al. A Polymerase Chain Reaction‐based Assay for the Rapid Detection of Gene Amplification in Human Tumors , 1996, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[15] R. McLendon,et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.
[16] J. Richardson,et al. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. , 2003, Blood.
[17] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[18] V. P. Collins,et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. , 1994, Oncogene.
[19] G. Tortora,et al. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] J. Villano,et al. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Roy S Herbst,et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] O. Wiestler,et al. Expression of the epidermal growth factor receptor in astrocytic tumours is specifically associated with glioblastoma multiforme , 2005, Virchows Archiv A.
[23] D. Osoba,et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.
[24] Manuel Hidalgo,et al. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. , 2003, Journal of the National Cancer Institute.
[25] A. Harris,et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] P. Humphrey,et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[27] Susan M. Chang,et al. 33 Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma , 2003 .
[28] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.